



Presentation 399-P / 399 Lower Rate of Hypoglycemia with IDegLira vs. Insulin Glargine Regardless of Dosing Time or Hypoglycemia Definition in Patients with Type 2 Diabetes


PAUL NORWOOD, ROGER C. CHEN, ELMAR JAECKEL, ILDIKO LINGVAY, HENRIK JARLOV, LUCINE LEHMANN, SIMON HELLER, *Fresno, CA, Concord, Australia, Hannover, Germany, Dallas, TX, Søborg, Denmark, Sheffield, United Kingdom*

Abstract:

In the DUAL V trial, patients assigned to insulin degludec/liraglutide (IDegLira) had greater A1c reduction (end of trial [EOT] A1c 6.6 vs. 7.1%) vs. insulin glargine (IG) with a significantly lower confirmed hypoglycemia rate (original definition: plasma glucose [PG] <56 mg/dL or unable to self-treat). This *post hoc* analysis investigated whether the lower hypoglycemia rate with IDegLira vs. IG was consistent irrespective of dosing time (AM [00:00-11:59] or PM [12:00-23:59]) or definition of hypoglycemia used (overall/nocturnal confirmed, with/without symptoms, ADA documented symptomatic). Hypoglycemia rates (episodes per patient-year exposure [PYE]) were significantly lower with IDegLira vs. IG, whether both were dosed at AM or PM, for confirmed hypoglycemia (AM: 2.18 vs. 6.86 PYE; PM: 2.26 vs. 4.59 PYE) and for nocturnal confirmed hypoglycemia (AM: 0.22 vs. 1.67 PYE; PM: 0.23 vs. 1.12 PYE) (Figure 1A). The rate of hypoglycemia was significantly lower for IDegLira vs. IG for confirmed (2.23 vs. 5.05 PYE), confirmed symptomatic (1.56 vs. 3.75 PYE) and ADA documented symptomatic (8.03 vs. 15.63 PYE) (Figure 1B). Nocturnal hypoglycemia rates were significantly lower (62-84%) for IDegLira vs. IG across the different definitions used. In conclusion, despite a lower EOT A1c, the hypoglycemia rate is lower with IDegLira vs. IG regardless of dosing time or hypoglycemia definition.



Figure. Estimated rate ratio of hypoglycemia for IDegLira vs IGLar by (A) dosing time and (B) according to hypoglycemia definition.



Number of hypoglycemic events are analyzed based on the full analysis set using a negative binomial regression model with a log link and the logarithm of the exposure time as offset. The model includes treatment and region as fixed effects. *One episode of severe hypoglycemia was reported in the trial, which was in the IGLar arm. CI, confidence interval; IDegLira, insulin degludec/liraglutide; IGLar, insulin glargine.